People with diabetes who used semaglutide or other GLP-1 agonists were also less likely to see a provider for depression.

Meshel Laurie has got candid about her whopping 60kg weight loss as she called for a controversial obesity medication to be added to the Pharmaceutical Benefits Scheme (PBS).

Ozempic and its counterparts, including Wegovy, Mounjaro and Zepbound, have surged in popularity as a means for weight loss, fueled by celebrity endorsements and slick pharmaceutical marketing.

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...

AstraZeneca has proposed price cuts to its drugs in the United States, its CEO said on Tuesday, days after unveiling a $50 ...

Novo Nordisk stock fell after the drugmaker unexpectedly cuts its full-year guidance, citing lower sales expectations for its ...